IL304597A - Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide - Google Patents

Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Info

Publication number
IL304597A
IL304597A IL304597A IL30459723A IL304597A IL 304597 A IL304597 A IL 304597A IL 304597 A IL304597 A IL 304597A IL 30459723 A IL30459723 A IL 30459723A IL 304597 A IL304597 A IL 304597A
Authority
IL
Israel
Prior art keywords
methyl
cyclopropanecarboxamido
triazol
pyridazine
carboxamide
Prior art date
Application number
IL304597A
Other languages
English (en)
Hebrew (he)
Inventor
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Victor W Rosso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80447586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL304597(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Victor W Rosso filed Critical Bristol Myers Squibb Co
Publication of IL304597A publication Critical patent/IL304597A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL304597A 2021-01-29 2023-07-19 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide IL304597A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143769P 2021-01-29 2021-01-29
PCT/US2022/014261 WO2022165141A1 (en) 2021-01-29 2022-01-28 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Publications (1)

Publication Number Publication Date
IL304597A true IL304597A (en) 2023-09-01

Family

ID=80447586

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304597A IL304597A (en) 2021-01-29 2023-07-19 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Country Status (11)

Country Link
US (2) US12129245B2 (https=)
EP (1) EP4284796B1 (https=)
JP (1) JP2024505063A (https=)
KR (1) KR20230137962A (https=)
CN (1) CN116829549A (https=)
AU (1) AU2022214313A1 (https=)
CA (1) CA3206254A1 (https=)
ES (1) ES3026120T3 (https=)
IL (1) IL304597A (https=)
MX (1) MX2023008651A (https=)
WO (1) WO2022165141A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
EP4387968B1 (en) * 2021-08-20 2025-11-12 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN116574056A (zh) * 2023-04-10 2023-08-11 五邑大学 一种氟代异喹啉酮类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) * 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
US12570637B2 (en) * 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide

Also Published As

Publication number Publication date
US20250154132A1 (en) 2025-05-15
US12129245B2 (en) 2024-10-29
ES3026120T3 (en) 2025-06-10
JP2024505063A (ja) 2024-02-02
EP4284796B1 (en) 2025-04-16
KR20230137962A (ko) 2023-10-05
CA3206254A1 (en) 2022-08-04
WO2022165141A1 (en) 2022-08-04
CN116829549A (zh) 2023-09-29
US20220259183A1 (en) 2022-08-18
MX2023008651A (es) 2023-08-01
AU2022214313A1 (en) 2023-08-17
EP4284796A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
IL304597A (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
AU2022214313A9 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
IL269594A (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
IL288508A (en) History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human ctps1 inhibitors to treat proliferative diseases
NZ611654A (en) Treatment of jak2-mediated conditions
RU2500673C2 (ru) Гетероциклические ингибиторы мек и способы их применения
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
RU2016110412A (ru) Некоторые химические соединения, композиции и способы
MX2025014307A (es) Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2)
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SI1702917T1 (en) The amide derivatives and the drug
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
IL282006A (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
RU2005102098A (ru) Амидное производное
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
RU2014112198A (ru) Синергические композиции ингибиторов pi3k и мек
JP2017534569A5 (https=)
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
TW201613888A (en) Crystalline forms of an NK-1 antagonist
JP2018516982A5 (ja) 免疫療法用組み合わせ組成物
BR112023004824A2 (pt) Formas de dosagem para inibidores tyk2 compreendendo núcleos intumescíveis
WO2022093610A8 (en) Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
RU2020115351A (ru) Лечение кожных заболеваний
IL308946A (en) Crystal form of (S,E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[3,2-D]pyrimidin-5-yl)phenyl )but-2-inamide free base
PT3980411T (pt) N-(5-(6-etoxipirazin-2-il)piridin-2-il)-4-(2-(etilsulfonamido)pirimidin-4-il)tetra-hidro-2h-piran-4-carboxamida como um inibidor de ctps1 humana para o tratamento de doenças proliferativas